Olumiant Clinical Prior Authorization Revision Effective March 27

Date: April 21, 2023

Attention: All Providers

Effective Date: March 27, 2023

Call to action: Texas Children’s Health Plan (TCHP) would like to inform providers that effective March 27, 2023, the Health and Human Services Commission (HHSC) revised the clinical prior authorization approval criteria for Olumiant, a Janus Kinase (JAK) Inhibitor. Olumiant is prescribed for adults with severe alopecia areata and adults with moderate to severely active rheumatoid arthritis. The prior authorization approval criteria revisions were made to match the information in the product package insert.

How this impacts providers: Effective March 27, 2023, the prior authorization approval criteria for Olumiant revision included an added diagnosis of alopecia areata, removed the check for OAT3 inhibitors for Olumiant, and revised the check for severe renal impairment (from < 60 mL/min/1.73m3 to < 30 mL/min/1.73m3) per updated prescribing information.

Next steps for providers: Prescribers can find the updated prior authorization form on the Navitus website. Prescribers should share this update with their staff.

If you have any questions, please email Provider Network Management at: providerrelations@texaschildrens.org.

For access to all provider alerts,log into:
www.thecheckup.org or www.texaschildrenshealthplan.org/for-providers.